RESOURCES

New FDA Guidance: Verification Systems for DSCSA

Late last week, the U.S. Food & Drug Administration (FDA) posted draft guidance on the Federal Register titled "Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs" to share their interpretation of the Drug Supply Chain Security Act (DSCSA) requirements for verification systems, processes in suspect or illegitimate product scenarios and saleable returns verification, and recommendations for cleared product notifications.

Read the summary of this DSCSA guidance, which was designed to help all industry stakeholders involved in verification processes to:

- Understand the information and business process expectations from the FDA given DSCSA requirements.
- Learn the FDA recommendations for managing verification.
- Determine how to manage the quarantine and investigation/disposal of suspect and illegitimate product.

BlogDSCSA for ManufacturersRegulatory/ComplianceUnited States
I want to learn more about verification from TraceLink.
Contact Us
I want to learn more about verification from TraceLink.

Related Content

FDA Pilot Report: Digital Recalls Network and DSCSA 2023 Traceability with Blockchain

See the results of TraceLink's FDA pilot project that focused on two workstreams; digital recalls and blockchain with participants from 22 companies across the supply chain
View More

DSCSA 2023: How Does the FDA Define “Suspect Product”?

Learn how recent FDA guidance provides more detailed definitions to help dispensers identify a suspect product.

View More



Case Study: TraceLink | FDA Pilot - Product Traceability Under 2023 DSCSA Regulations - A Business Process-Led Design for a Blockchain Network

TraceLink's breakthrough blockchain solution, Trace Histories, can help pharma customers comply with US DSCSA regulations that go into effect in 2023.

View More